On May 2^nd, 2025, the Investigational New Drug (IND) application for ZHB114 for Injection—a Class I innovative biologic drug independently developed by Zonhonbio with proprietary intellectual property rights—was officially approved by the U.S. Food and Drug Administration (FDA). The newly approved indication covers advanced malignant tumors.